Creatinine News and Research

RSS

Real-world data confirm TDF efficacy for HBV

Treatment with tenofovir disoproxil fumarate elicits sustained virological responses and exhibits a favourable safety profile in a diverse population of patients with chronic hepatitis B virus infection, shows a French routine clinical practice study.

10 Mar 2016

FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

Allergan plc, a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for DALVANCE (dalbavancin) for injection.

21 Jan 2016

Dynamic light scattering technique may help detect people at risk of cataracts and presbyopia

As we age, proteins in the lenses of our eyes start misbehaving: They unfold and congregate in clusters that block, scatter and distort light as it passes through the lens. A cloudy area, or cataract, forms. In a new study, scientists found that throughout our lifetime, levels of a key protein decline, and may be an early warning sign of a developing cataract.

23 Dec 2015

Zurampic (lesinurad) approved to treat high levels of hyperuricemia associated with gout

The U.S. Food and Drug Administration today approved Zurampic (lesinurad) to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, when used in combination with a xanthine oxidase inhibitor (XOI), a type of drug approved to reduce the production of uric acid in the body.

22 Dec 2015

Mayo Clinic researchers report national trend toward overtesting HbA1C levels in diabetes patients

In a study released online today in The BMJ, researchers from Mayo Clinic report a national trend toward overtesting glycated hemoglobin (HbA1C) levels in adult patients with Type 2 diabetes.

9 Dec 2015

New article reveals link between poor kidney function, worse outcomes after heart surgery

Poor kidney function prior to heart surgery can lead to worse outcomes, higher surgical costs, and a longer hospital stay, according to an article posted online today by The Annals of Thoracic Surgery.

9 Dec 2015

Personalised peptide vaccination promising in bladder cancer

Metastatic bladder cancer patients who have progressed on first-line platinum-based chemotherapy could derive survival benefits from personalised peptide vaccination, according to phase II trial results.

27 Nov 2015

U.S. adults who use smokeless tobacco products have higher levels of nicotine, carcinogen

U.S. adults who used only smokeless tobacco products had higher levels of biomarkers of exposure to nicotine and a cancer-causing toxicant -- the tobacco-specific nitrosamine NNK -- compared with those who used only cigarettes

19 Nov 2015

White coat hypertension, masked hypertension increase cardiovascular events over the years

Patients whose blood pressures spikes in the doctor's office but not at home, and patients whose blood pressure spikes at home but not in the doctor's office, suffer more heart attacks, heart failure, and strokes than patients with normal blood pressures in both settings, UT Southwestern Medical Center researchers have found.

10 Nov 2015

Presence of tophi in people with gout can increase risk of developing cardiovascular disease

The presence of tophi - crystal deposits of uric acid found on the surface of the joints or in the skin and cartilage - in people with gout can increase their risk of developing cardiovascular disease, according to research presented this week at the American College of Rheumatology Annual Meeting in San Francisco.

9 Nov 2015

Circulating protein predicts risk of chronic kidney disease

Make room, cholesterol. A new disease marker is entering the medical lexicon: suPAR, or soluble urokinase-type plasminogen activator receptor.

6 Nov 2015

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan plc today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego.

8 Oct 2015

Certain laboratory results can help to predict survival in patients with brain metastases

A new MedUni Vienna study conducted in the Comprehensive Cancer Centre (CCC) Vienna shows that certain laboratory results, which have previously not been used specifically for this purpose, can help to predict survival in patients with newly diagnosed brain metastases and to decide on the most appropriate treatment strategy.

26 Sep 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Allergan plc. today announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ (ceftazidime-avibactam) as a treatment for adult hospitalized patients with complicated urinary tract infections (cUTI), including pyelonephritis.

2 Sep 2015

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Among patients with diabetes and kidney disease, most receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, the addition of the medication finerenone compared with placebo resulted in improvement in albuminuria (the presence of excessive protein [chiefly albumin] in the urine), according to a study in the September 1 issue of JAMA.

2 Sep 2015

ATTEMPT-CVD trial results show that ARBs may have better impact on CVD biomarkers

When it comes to treating high blood pressure, not all anti-hypertensive medications are equal, and results of the ATTEMPT-CVD trial suggest that telmisartan, an angiotensin II receptor blocker (ARB) might have benefits over non-ARB treatment.

31 Aug 2015

MRA therapy does not improve outcome in heart attack patients without heart failure

Heart attack patients without heart failure derive no benefit from the addition of mineralocortoid receptor antagonists (MRA), to standard therapy, results of the ALBATROSS study show.